The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Alexion Pharmaceuticals Inc | COM | 015351109 | 119,492 | 650,440 | SH | SOLE | 650,440 | 0 | 0 | ||
| Alkermes PLC | SHS | G01767105 | 291,052 | 11,870,000 | SH | SOLE | 11,870,000 | 0 | 0 | ||
| BioCryst Pharmaceuticals Inc | COM | 09058V103 | 67,366 | 4,261,000 | SH | SOLE | 4,261,000 | 0 | 0 | ||
| BIOGEN INC | COM | 09062X103 | 222,651 | 643,000 | SH | SOLE | 643,000 | 0 | 0 | ||
| Gilead Sciences Inc | COM | 375558103 | 185,742 | 2,697,400 | SH | SOLE | 2,697,400 | 0 | 0 | ||
| INNOVIVA INC | COM | 45781M101 | 86,011 | 6,414,000 | SH | SOLE | 6,414,000 | 0 | 0 | ||
| INTERCEPT PHARMACEUTICALS INC | COM | 45845P108 | 18 | 950 | SH | SOLE | 950 | 0 | 0 | ||
| IRONWOOD PHARMACEUTICALS INC | COM CL A | 46333X108 | 210,939 | 16,390,000 | SH | SOLE | 16,390,000 | 0 | 0 | ||
| JAZZ PHARMACEUTICALS PLC | SHS USD | G50871105 | 177 | 1,000 | SH | SOLE | 1,000 | 0 | 0 | ||
| MERSANA THERAPEUTICS INC | COM | 59045L106 | 54,396 | 4,005,600 | SH | SOLE | 4,005,600 | 0 | 0 | ||
| MIRATI THERAPEUTICS INC | COM | 60468T105 | 161 | 1,000 | SH | SOLE | 1,000 | 0 | 0 | ||
| SARISSA CAPITAL ACQUISITN CO | W EXP 10/23/202 | G7823W110 | 4,999 | 3,333,333 | SH | SOLE | 3,333,333 | 0 | 0 | ||
| REGULUS THERAPEUTICS INC | COM NEW | 75915K200 | 1,506 | 1,851,851 | SH | SOLE | 1,851,851 | 0 | 0 | ||
| VOR BIOPHARMA INC | COM | 929033108 | 13,186 | 707,010 | SH | SOLE | 707,010 | 0 | 0 | ||